Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans

Drug Metabolism and Disposition

Volumn 42, Issue 5, 2014, Pages 818-827

  Kassahun, Kelem ^a   McIntosh, Ian ^a   Koeplinger, Kenneth ^a   Sun, Li ^a   Talaty, Jennifer E ^a   Miller, Deborah L ^a   Dixon, Russell ^b   Zajic, Stefan ^a   Stoch, S Aubrey ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Covance Clinical Research ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; DRUG METABOLITE; ODANACATIB; BIPHENYL DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CATHEPSIN K; CTSK PROTEIN, HUMAN; CYTOCHROME P450; MULTIDRUG RESISTANCE PROTEIN;

ADULT; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; FECES; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; URINE; VOLUNTEER; ADOLESCENT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOTRANSFORMATION; CELL CULTURE; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; ENZYME SPECIFICITY; ENZYMOLOGY; LIVER CELL; LIVER MICROSOME; METABOLISM; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RAT; TISSUE DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; BIOTRANSFORMATION; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; CATHEPSIN K; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; FECES; HEPATOCYTES; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; P-GLYCOPROTEIN; RATS; SUBSTRATE SPECIFICITY; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84898825690     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.056580     Document Type: Article

References (20)

1. Baron R and Hesse E (2012) Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 97:311-325.
2. Bone HG, McClung MR, Roux C, Recker RR, Eisman JA, Verbruggen N, Hustad CM, DaSilva C, Santora AC, and Ince BA (2010) Odanacatib, a cathepsin-K inhibitor for osteoporosis: a twoyear study in postmenopausal women with low bone density. J Bone Miner Res 25:937-947.
3. Brixen K, Chapurlat R, Cheung AM, Keaveny TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N, and Ather S, et al. (2013) Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 98:571-580.
4. Compston J (2010) Osteoporosis: social and economic impact. Radiol Clin North Am 48: 477-482.
5. Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel DB, Scott BB, and Duong T (2012) Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 27:524-537.
6. Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR, Rizzoli R, Resch H, Verbruggen N, Hustad CM, and DaSilva C, et al. (2011) Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 26:242-251.
7. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong T, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, and LeRiche T, et al. (2008) The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18:923-928.
8. Gu J, Zhong D, and Chen X (1999) Analysis of O-glucuronide conjugates in urine by electrospray ion trap mass spectrometry. J Anal Chem 365:553-558.
9. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, and Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136.
10. Iki M (2012) [Epidemiology of osteoporosis in Japan]. Clin Calcium 22:797-803.
11. Kassahun K, Black WC, Nicoll-Griffith D, McIntosh I, Chauret N, Day S, Rosenberg E, and Koeplinger K (2011) Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin K inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway. Drug Metab Dispos 39:1079-1087.
12. Krimmer HP, Drauz K, and Kleeman A (1987) Reaction of beta-mercapto alpha-amino acids with nitriles. Chemiker-Zeitung 111:357-361.
13. Masarachia PJ, Pennypacker BL, Pickarski M, Scott KR, Wesolowski GA, Smith SY, Samadfam R, Goetzmann JE, Scott BB, and Kimmel DB, et al. (2012) Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 27:509-523.
14. Rachner TD, Khosla S, and Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377: 1276-1287.
15. Stoch SA and Wagner JA (2008) Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 83:172-176.
16. Stoch SA, Witter R, Hreniuk D, Liu C, Zajic S, Mehta A, Brandquist C, Dempsey C, Degroot B, and Stypinski D, et al. (2013a) Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration. Int J Clin Pharmacol Ther 51: 688-692.
17. Stoch SA, Witter R, Hrenuik D, Liu C, Zajic S, Mehta A, Chandler P, Morris D, Xue H, and Denker A, et al. (2013b) Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin. J Popul Ther Clin Pharmacol 20:e312-e320.
18. Stoch SA, Zajic S, Stone JA, Miller DL, van Bortel L, Lasseter KC, Pramanik B, Cilissen C, Liu Q, and Liu L, et al. (2013c) Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics-results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 75:1240-1254.
19. Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez MJ, De Decker M, Liu L, Liu Q, and Scott BB, et al. (2009) Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebocontrolled phase I studies. Clin Pharmacol Ther 86:175-182.
20. Sun L, Forni S, Schwartz MS, Breidinger S, and Woolf EJ (2012) Quantitative determination of odanacatib in human plasma using liquid-liquid extraction followed by liquid chromatographytandem mass spectrometry analysis. J Chromatogr B Analyt Technol Biomed Life Sci 885-886: 15-23.